Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fosun Pharma To Participate In Consolidated Listing Of Small Pharmaceutical Firms

This article was originally published in PharmAsia News

Executive Summary

Small- and mid-sized pharmaceutical enterprises in China are facing especially tough times due to bottlenecks such as brand building and fund shortages. A group of small and medium firms in Beijing has announced its intention last April to band together and negotiate to bring investments public. Fosun Pharma has expressed interest and is having preliminary contact with the companies. If successful, the partnership will become a new model for China's pharmaceutical development. However, industry analysts observe that establishing such a venture comes with major challenges like the evaluation of each party's assets and securing government support. To address these issues, Beijing Pharmaceutical Profession Association will hold a meeting with 10 Beijing pharmaceutical enterprises to discuss the collaboration. (Click here for more - Chinese Language)

You may also be interested in...



UN Rejects Proposal To Exempt CBD From International Narcotics Controls

A WHO recommendation to explicitly exempt low-THC CBD from international narcotics controls has been emphatically rejected by UN member states. The CBD industry had hoped for a positive outcome to remove regulatory pressure on product manufacturers in Europe and around the world. 

Coronavirus Update: After UK Nod, New Forecast Makes Pfizer Vaccine The Leader

After its historic first emergency approval, analysts at Bernstein has upgraded predictions for Pfizer/BioNTech's COVID-19 vaccine in 2021 and beyond.

Compare And Contrast: New UKCA Marking System Will Stress Safety, Quality and Agility

How UK and EU device regulations will differ in 2021, UK approved bodies and Northern Ireland's unfettered access to the UK market were key themes at the ABHI’s annual regulatory conference.

UsernamePublicRestriction

Register

OM013133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel